PDT Partners’s Achillion Pharmaceuticals ACHN Stock Holding History

PDT Partners’s Portfolio ACHN Stock Details ACHN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-69,391	Closed	-$110K	–	533
2018 Q4	$110K	Sell	69,391 -51,709	-43%	-$146K	0.01%	439
2018 Q3	$446K	Sell	121,100 -26,800	-18%	-$79.9K	0.02%	369
2018 Q2	$419K	Sell	147,900 -74,600	-34%	-$254K	0.02%	413
2018 Q1	$825K	Buy	+222,500	New	+$728K	0.03%	378
2017 Q4	–	Sell	-216,000	Closed	-$970K	–	586
2017 Q3	$970K	Hold	216,000	–	–	0.03%	359
2017 Q2	$991K	Sell	216,000 -72,000	-25%	-$289K	0.04%	339
2017 Q1	$1.21M	Buy	288,000 +88,569	+44%	+$368K	0.06%	295
2016 Q4	$824K	Sell	199,431 -85,469	-30%	-$454K	0.05%	353
2016 Q3	$2.31M	Sell	284,900 -700	-0.2%	-$5.95K	0.14%	207
2016 Q2	$2.23M	Buy	285,600 +700	+0.2%	+$6K	0.18%	188
2016 Q1	$2.2M	Buy	284,900 +62,300	+28%	+$456K	0.14%	229
2015 Q4	$2.4M	Buy	+222,600	New	+$2.02M	0.33%	138
2015 Q2	–	Sell	-99,200	Closed	-$978K	–	1765
2015 Q1	$978K	Buy	99,200 +43,300	+77%	+$541K	0.02%	795
2014 Q4	$685K	Buy	+55,900	New	+$683K	0.07%	408
2013 Q3	–	Sell	-73,291	Closed	-$600K	–	1810
2013 Q2	$600K	Buy	+73,291	New	+$559K	0.01%	996

Other funds holding ACHN

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

MCO

MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

PDT Partners's ACHN Position: Q1 2019 in Review

PDT Partners sold out of Achillion Pharmaceuticals (ACHN) in Q1 2019, closing a stake of 69,391 shares — an estimated $110K sold.

PDT Partners first reported a position in ACHN in Q2 2013 and held it in 15 quarters. The position peaked at $2.4M in Q4 2015. 110 funds tracked by Wall St. Rank hold ACHN as of Q1 2019.

PDT Partners reported no remaining Achillion Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
PDT Partners sold 69,391 Achillion Pharmaceuticals shares in Q1 2019, an estimated $110K.
PDT Partners first reported a position in Achillion Pharmaceuticals in Q2 2013 and held it in 15 quarters.
PDT Partners's Achillion Pharmaceuticals position peaked at $2.4M in Q4 2015.
110 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q1 2019.

Based on PDT Partners's 13F filing for Q1 2019, filed 15 May 2019.